Conversations in Drug Development Trends

AUGUST 14, 2024

The analysis of circulating tumor DNA (ctDNA) in a liquid biopsy can also permit genotyping and help monitor the effectiveness of chemotherapy. Check out our white paper to learn more about our services, or contact our team to find out how we can help support your oncology drug development program.

Treatment 78

Treatment Therapies Disease Protein Expression 78

Codon

APRIL 30, 2023

Yeast die for two reasons: Either their nucleolus (where the DNA is kept) degrades and dies, or their mitochondria whimpers out and they stop making energy. The vaccine printer can make lots of different types of vaccines, including protein, DNA, and mRNA ones, but I’m sure this is all quite expensive right now. From Zhang et al.

Vaccine 52

Vaccine DNA Engineering RNA 52

Codon

APRIL 30, 2023

Yeast die for two reasons: Either their nucleolus (where the DNA is kept) degrades and dies, or their mitochondria whimpers out and they stop making energy. The vaccine printer can make lots of different types of vaccines, including protein, DNA, and mRNA ones, but I’m sure this is all quite expensive right now. From Zhang et al.

Vaccine 52

Vaccine DNA Engineering RNA 52

Agency IQ

JULY 21, 2023

The next chapter in the ctDNA story: Still promising, not ready for prime time A recent workshop summed up the state of play for circulating tumor DNA. As dying cancer cells degrade, their cell contents are released into the patient’s circulation, affording the possibility of detecting fragments of DNA that are unique to the cancer.

FDA 40

FDA Clinical Trials Treatment Trials 40

The Pharma Data

MARCH 20, 2021

DNA biomarker services in an accredited environment. Bioinformatics in the Faculty. of Medicine and Health Sciences (Ghent University) and. also the co-founder and CSO of. Biogazelle, an innovative bioanalytical services company offering RNA and. In April 2020, Biogazelle introduced a high-throughput, modular and scalable SARS-CoV-2 RT-qPCR.

Laboratories 52

Laboratories Virus RNA Bioinformatics 52

Conversations in Drug Development Trends

APRIL 7, 2025

Liquid biopsies, particularly those that detect circulating tumor DNA amongst other known blood-based biomarkers, make the screening process less invasive and more approachable to patients who already undergo multiple blood draws daily, reducing participation burden. Request early access here for the white paper.

Research 40

Research Clinical Trials Trials Clinical Research 40